Doctors at the All India Institute of Medical Sciences (AIIMS), New Delhi, have begun research into a new treatment approach aimed at slowing the growth of glioblastoma, one of the most aggressive forms of cancerous brain tumour. The study is examining the combined use of Gamma Knife radiosurgery and a low dose of the cancer drug Bevacizumab.
The initial findings indicate that this combination may help control tumour progression and reduce associated swelling. Researchers are exploring whether the approach could provide an additional treatment option for patients waiting for surgery.
Treatment During the Waiting Period
According to Professor Deepak Agrawal of the AIIMS Neurosurgery Department, the large number of patients at government hospitals can result in lengthy waiting periods for surgical procedures. In some cases, patients may have to wait more than three months after diagnosis.
For an aggressive tumour such as glioblastoma, such delays can be particularly concerning. The research team is therefore investigating whether treatment can begin before surgery to help manage the disease during the waiting period.
Combination of Radiation and Medication
The approach combines Gamma Knife radiosurgery with a low dose of Bevacizumab. The drug may help reduce the blood supply associated with tumour growth and control swelling around the affected area.
Researchers are examining whether this combination can make subsequent surgery safer and help doctors remove the tumour more effectively. Its possible use before and after surgery is also being studied.
Glioblastoma Remains a Major Medical Challenge
Glioblastoma is among the most aggressive primary malignant brain tumours in adults. Despite surgery, radiation therapy and chemotherapy, the average survival period for patients is generally around 14 to 16 months.
The research, titled Upfront Gamma Knife with Concomitant Bevacizumab: A Game Changer in Glioblastoma Management, has been published in the November issue of the journal Interdisciplinary Neurosurgery: Advanced Techniques and Case Management.
The research team includes Dr Mahnaz Sultana Azim, Dr Satish Kumar Verma and Dr Shailesh Gaikwad, along with Dr Deepak Agrawal.
The findings are preliminary and further research is needed to establish the treatment's safety and effectiveness. The approach is not yet a proven replacement for standard glioblastoma treatment.
Hashtags: #DelhiState #Delhi #Aiims #Studies #New #Approach #Slow #Aggressive #Brain #AIIMSStudiesNewApproach

